COX-2 INHIBITORS MAY PREVENT CANCER

A French journal devoted an entire issue to studies showing that the cox-2 inhibitors (Celebrex and Vioxx) that are prescribed for arthritis may also help prevent cancers of the skin and intestines, colon and stomach.

Certain cancers produce chemicals that cause blood vessels to grow and bring them blood and nutrition. Without increased blood flow, these cancers will die. Swelling and irritation, called inflammation by doctors, cause the body to produce large amounts of Cox-2 hormones that cause redness, itching and swelling. Cox-2 inhibitors, such as Celebrex and Vioxx, treat the swelling and pain of arthritis. Cox-2 hormones also increase blood vessels that bring blood to cancers. Cox-2 inhibitors such as Vioxx and Celebrex also block blood flow to prevent and treat certain cancers. However, Vioxx was taken off the market in 2004 and Celebrex now has warning labels.

1) Cyclooxygenase-2: a new target for epithelial cancer treatments - Arachidonic acid and prostaglandins, inflammation and oncology.P Eschwege, V deLedinghen, T Camilli, S Kulkarni, G Dalbagni, S Droupy, A Jardin, G Benoit, BB Weksler. Presse Medicale, 2001, Vol 30, Iss 10, pp 508-510. Address Eschwege P, Hop Bicetre, Serv Urol, AP HP, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, FRANCE.

2) Cyclooxygenase-2: a new target for epithelial cancer treatments - Cyclooxygenases. P Eschwege, V deLedinghen, T Camilli, S Kulkarni, G Dalbagni, S Droupy, A Jardin, G Benoit, BB Weksler. Presse Medicale, 2001, Vol 30, Iss 10, pp511-514. Address Eschwege P, Hop Bicetre, Serv Urol, AP HP, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, FRANCE. 3)Cyclooxygenase-3: a new target far epithelial cancer treatments - Cyclooxygenase inhibitors. P Eschwege, V deLedinghen, T Camilli, S Kulkarni, G Dalbagni, S Droupy, A Jardin, G Benoit, BB Weksler. Presse Medicale, 2001, Vol 30, Iss 10, pp 515-517. Address Eschwege P, Hop Bicetre, Serv Urol, AP HP, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, FRANCE

Reported 4/19/01; checked 8/9/05

Get our newsletter